Cita APA

de Bono, J., Molife, L., Sonpavde, G., Maroto, J., Calvo, E., Cartwright, T., . . . Petrylak, D. (2012). Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.

Citación estilo Chicago

de Bono, JS, et al. Phase II Study of Eribulin Mesylate (E7389) in Patients With Metastatic Castration-resistant Prostate Cancer Stratified By Prior Taxane Therapy. 2012.

Cita MLA

de Bono, JS, et al. Phase II Study of Eribulin Mesylate (E7389) in Patients With Metastatic Castration-resistant Prostate Cancer Stratified By Prior Taxane Therapy. 2012.